|
Study
|
Year
|
Number of patients
|
Cut-off value
|
Prognosis (high vs low NLR)
|
Hazard ratio (low NLR was set as 1)
|
|---|
|
Bladder
|
|
Gondo et al. [28]
|
2012
|
189
|
2.5
|
not mentioned (OS)
|
1.946, p==0.0015
|
|
Demirtas et al. [2]
|
2013
|
201
|
2.5
|
no significant differences
|
N/A
|
|
Krane et al. [37]
|
2013
|
68
|
2.5
|
23 vs 36 months (CSS)
|
2.25
|
|
Hermanns et al. [26]
|
2014
|
424
|
3
|
43 % vs 64 % (OS)
|
1.67, p < 0.001
|
|
Temraz et al. [38]
|
2014
|
68
|
2.87
|
2.7 vs 6.0 years (OS)
|
1.88
|
|
Mano et al. [33]
|
2014
|
107 (NMIBC)
|
2.41
| |
3.74, p = 0.004
|
|
Viers et al. [39]
|
2014
|
unknown
|
unknown
| |
1.03, p = 0.01
|
|
Kayner et al. [40]
|
2014
|
291
|
2.50
|
NMIBC vs MIBC
|
p = 0.028
|
|
Current study
|
2014
|
74
|
2.38
|
52.6 vs 51.7 months (OS)
|
4.84, p = 0.007
|
|
Upper urinary tract
|
|
Azuma et al. [41]
|
2013
|
137
|
2.5
|
29.4 % vs 81.3 % (OS)
|
6.14, p < 0.0001
|
|
Dalpiaz et al. [9]
|
2013
|
202
|
2.7
|
27 vs 44.5 months (OS)
|
3.073, p < 0.001
|
- NLR: neutrophil-to-lymphocyte ration, NMIBC: non-muscle-invasive bladder cancer, MIBC: muscle-invasive bladder cancer, OS: overall survival, CSS: cancer-specific survival
